Novocure’s Optune Gio fails to show benefit at earlier stage
The Phase III TRIDENT study failed to show statistical significance in OS when Optune Gio was used earlier.
Therapy Area
Parkinson’s disease: neuromodulation and the search for disease modification
Roche’s Elecsys NfL test earns CE mark for multiple sclerosis detection
Non-invasive diagnostics in endometriosis: at the cusp of a turning point
Daiichi and GAIA join forces to commercialise digital cardiovascular therapy
Guardant Health acquires MetaSight amid positive 2026 financial outlook
UK’s NICE greenlights Abbott’s CardioMEMS heart failure sensor
Pulse Biosciences and MD Anderson to study nPulse for thyroid cancer
